Bio Essence Corp (BIOE) Form 10-Q — Aug 14, 2026
Bio Essence Corp's 10-Q for the quarter ended June 30, 2026 shows a dramatic turnaround: six-month revenue jumped 360.43% to $1,295,248 on surging OEM supplement orders from two new major customers, swinging the company from a $145,888 net loss to net income of $475,450 and restoring positive stockholders' equity of $2.3 million. Liquidity remains dire despite the profits. The company held just $675 in cash against a $998,524 working capital deficit and a $9.1 million accumulated deficit, and management's going-concern substantial doubt persists, with roughly $1.2 million needed to fund operations over the next 12 months.
Key figures
- Eps
- 0.01
- Revenue
- 1295248
- Net Income
- 475450
- Total Debt
- 56836
- Revenue Yoy
- +360.43%
- Cash Position
- 675
- Shares Outstanding
- 53809000
- Q2 Revenue
- 794711
- Q2 Net Income
- 270077
- Current Ratio
- 0.38:1
- Q2 Revenue Yoy
- +206.69%
- Related Party Loan
- 500000
- Litigation Accrual
- ~$1.5 million
- Accumulated Deficit
- 9077623
- Stockholders Equity
- 2342557
- Gross Profit Six Months
- 789614
- Medi Flow AIShare Price
- 0.5
- Related Party Loan Rate
- 5%
- Working Capital Deficit
- 998524
- Cash Needed Next12 Months
- 1200000
- Medi Flow AIShares Issued
- 7000000
- Private Placement Shares
- 8800000
- Litigation Damages Sought
- 1504823.81
- Medi Flow AIConsideration
- 3500000
- Private Placement Proceeds
- 440000
- Related Party Loan Maturity
- June 30, 2027
- Share Count Increase Six Months
- 41.6%
- Private Placement Price Per Share
- 0.05
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.